Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo toxicity study of Dittrichia viscosa (L.) greuter fractions: evidence of safety for oral and dermal applications.

Scientific reports·2026
Same author

Effects of exposure to negative and positive social media content about vaping and nicotine addiction on beliefs and intentions to use e-cigarettes among young adults in the U.S.: results from a randomized controlled experiment.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026
Same author

Development and Psychometric Testing of a Scale Evaluating Traditional Health Practices for Cervical Cancer Prevention Among Haitian Migrant Women.

Psycho-oncology·2026
Same author

Cervical cancer information access and dissemination strategies among rural Kenyan women: A mixed methods study.

Journal of public health in Africa·2026
Same author

Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study.

Therapeutic advances in drug safety·2026
Same author

Pregnant women's attitudes and intentions toward tuberculosis, malaria, group B streptococcus, and respiratory syncytial virus vaccines in pregnant: Findings from a cross-sectional study of pregnant women living in Brazil, Ghana, Kenya, and Pakistan.

PLOS global public health·2026

Related Experiment Video

Updated: Jun 7, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K

Evidence for an HPV one-dose schedule.

Margaret Stanley1, Anne Schuind2, Kirthini K Muralidharan3

  • 1Department of Pathology, University of Cambridge, Tennis Court Rd, Cambridge, CB2 1QP, United Kingdom.

Vaccine
|November 9, 2024
PubMed
Summary
This summary is machine-generated.

The World Health Organization now recommends a single human papillomavirus (HPV) vaccine dose. Evidence from trials, studies, and modeling supports its effectiveness, simplifying global immunization strategies.

Keywords:
Dosing ScheduleHPV VaccineImmunisation Programmes

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.3K

Related Experiment Videos

Last Updated: Jun 7, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.3K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.3K

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The human papillomavirus (HPV) is a common virus linked to several cancers.
  • Traditional HPV vaccination schedules involved two or three doses.
  • Recent global health recommendations have shifted towards a simplified dosing regimen.

Purpose of the Study:

  • To evaluate the scientific basis for a single-dose HPV vaccine schedule.
  • To analyze the evidence supporting the efficacy and immunogenicity of one dose.
  • To explore the public health implications of adopting a single-dose HPV vaccination strategy.

Main Methods:

  • Review of biologic plausibility studies for single-dose HPV vaccination.
  • Analysis of clinical trial data on single-dose HPV vaccine efficacy.
  • Examination of post-licensure observational studies and mathematical modeling.
  • Assessment of national immunization program transitions to single-dose schedules.

Main Results:

  • Biologic plausibility supports a single-dose HPV vaccine regimen.
  • Clinical trials and observational data demonstrate high efficacy with one dose.
  • Mathematical models confirm the public health benefits of a single-dose strategy.
  • Several countries have successfully implemented single-dose HPV vaccination.

Conclusions:

  • A single-dose HPV vaccine schedule is biologically plausible and supported by robust evidence.
  • Switching to a single-dose schedule simplifies logistics and can increase vaccine coverage.
  • Global adoption of a single-dose HPV vaccine strategy is feasible and beneficial for public health.